<DOC>
	<DOCNO>NCT00143663</DOCNO>
	<brief_summary>The purpose study determine patient elevate cholesterol , take lipid medication , could lower cholesterol administration lapaquistat acetate , daily ( QD ) .</brief_summary>
	<brief_title>Effect Lapaquistat Acetate Blood Cholesterol Levels Subjects With Elevated Cholesterol</brief_title>
	<detailed_description>This study evaluate efficacy safety TAK-475 ( lapaquistat acetate ) compare placebo subject primary hypercholesterolemia . Subjects sign informed consent undergo necessary evaluation determine eligibility dietary run-in phase . Subjects meet randomization criterion enter treatment one follow randomized treatment : lapaquistat acetate placebo .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Female participant childbearing potential pregnant , lactate plan become pregnant agrees use acceptable form contraception throughout course study . Must mean lowdensity lipoprotein cholesterol value 3.367 5.689 mmol/L , inclusive , 2 consecutive sample take least 1 week apart difference 2 value exceed 15 % high value . Must triglyceride value 4.516 mmol/L less 2 consecutive sample take least 1 week apart upper value either sample 5.081 mmol/L le . Has clinical laboratory evaluation within reference range test laboratory unless result deem clinically significant investigator sponsor . Is willing able maintain standardize lowcholesterol diet . Has alanine aminotransferase aspartate aminotransferase level great 1.5 time upper limit normal , active liver disease jaundice . Has serum creatinine level great 135 Î¼mol/L . Has creatine phosphokinase value great three time upper limit normal . Has diabetes mellitus type 1 2 . Has history cancer remission le 5 year prior first dose study drug . This criterion include subject basal cell stage I squamous cell carcinoma skin . Has endocrine disorder , Cushing syndrome , hyperthyroidism , inappropriately treated hypothyroidism , affect lipid metabolism . Has history myocardial infarction , angina pectoris , transient ischemic attack , cerebrovascular accident , peripheral vascular disease , abdominal aortic aneurysm , coronary revascularization multiple risk factor present 10year risk CHD great 20 % , base Framingham risk scoring . Has positive hepatitis B surface antigen hepatitis C virus antibody , determine medical history and/or participant 's verbal report . Has positive human immunodeficiency virus test result take antiretroviral medication , determine medical history and/or subject 's verbal report . Is unable unwilling discontinue exclude medication continue stable dos `` stable dose '' medication would require treatment excluded medication study . Has exposure lapaquistat acetate study participate enrol another investigational study within previous 30 day , drug long halflife , within period le 5 time drug 's halflife . Has history presence clinically significant food allergy would prevent adherence therapeutic lifestyle change ( equivalent ) diet . Has know heterozygous homozygous familial hypercholesterolemia know type III hyperlipoproteinemia ( familial dysbetalipoproteinemia ) . Has fibromyalgia , myopathy , rhabdomyolysis , unexplained muscle pain . Has uncontrolled hypertension . Has inflammatory bowel disease malabsorption syndrome gastric bypass surgical procedure weight loss . Has history drug abuse alcohol abuse within past 2 year . Has serious disease condition RunIn Randomization might reduce life expectancy , impair successful management accord protocol , make subject unsuitable candidate receive study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>